Medically reviewed by Karina Tolentino, RD Metastatic breast cancer (MBC) and the therapies used to treat it can adversely ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

A review was conducted to compare postsurgical outcomes for patients with breast cancer who received rehabilitation nursing with outcomes for those who received traditional nursing.